肝X受体
脂毒性
甾醇调节元件结合蛋白
脂肪变性
胆固醇
甾醇
生物信息学
生物
生物化学
化学
药理学
内分泌学
基因
核受体
转录因子
胰岛素抵抗
胰岛素
作者
Yuwei Fang,Jianglian She,Xi Zhang,Tanwei Gu,Danni Xie,Xiaowei Luo,Xiangxi Yi,Chenghai Gao,Yonghong Liu,Cui‐Xian Zhang,Lan Tang,Xuefeng Zhou
标识
DOI:10.1021/acs.jnatprod.3c01029
摘要
A strategy integrating in silico molecular docking with LXRα and phenotypic assays was adopted to discover anti-hypercholesterolemia agents in a small library containing 205 marine microorganism-derived natural products, collected by our group in recent years. Two fumitremorgin derivatives, 12 R,13 S -dihydroxyfumitremorgin C ( 1 ) and tryprostatin A ( 3 ), were identified as potential LXRα agonists, by real-time qPCR and Western blot (WB) analysis, together with a surface plasmon resonance (SPR) assay. The anti-hypercholesterolemic effects of 1 and 3, together with their mechanisms, were investigated in depth using different cell and mouse models, among which the study of LXRα is of crucial importance. Compound 1 or 3 exhibited the capacity to effectively reverse excessive lipid accumulation in a hepatic steatosis cell model and significantly reduce liver damage and blood cholesterol levels in high cholesterol diet (HCD)-fed wild-type mice, whereas those beneficial effects were completely nullified in HCD-fed LXRα-knockout mice. Furthermore, 1 and 3 outperformed common LXRα agonists by suppressing the expression of sterol regulatory element-binding protein 1 (SREBP1) in HCD-fed mice, mitigating lipotoxicity. Thus, this study highlights the discovery of two marine microorganism-derived anti-hypercholesterolemia agents targeting LXRα.
科研通智能强力驱动
Strongly Powered by AbleSci AI